Contribution of Metabolomics to the Understanding of NAFLD and NASH Syndromes: A Systematic Review.

metabolic syndrome metabolomics non-alcoholic fatty liver disease non-alcoholic steatohepatitis

Journal

Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790

Informations de publication

Date de publication:
11 Oct 2021
Historique:
received: 31 08 2021
revised: 03 10 2021
accepted: 06 10 2021
entrez: 22 10 2021
pubmed: 23 10 2021
medline: 23 10 2021
Statut: epublish

Résumé

Several differential panels of metabolites have been associated with the presence of metabolic syndrome and its related conditions, namely non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). This study aimed to perform a systematic review to summarize the most recent finding in terms of circulating biomarkers following NAFLD/NASH syndromes. Hence, the research was focused on NAFLD/NASH studies analysed by metabolomics approaches. Following Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines, a systematic search was conducted on the PubMed database. The inclusion criteria were (i) publication date between 2010 and 2021, (ii) presence of the combination of terms: metabolomics and NAFLD/NASH, and (iii) published in a scholarly peer-reviewed journal. Studies were excluded from the review if they were (i) single-case studies, (ii) unpublished thesis and dissertation studies, and (iii) not published in a peer-reviewed journal. Following these procedures, 10 eligible studies among 93 were taken into consideration. The metabolisms of amino acids, fatty acid, and vitamins were significantly different in patients affected by NAFLD and NASH compared to healthy controls. These findings suggest that low weight metabolites are an important indicator for NAFLD/NASH syndrome and there is a strong overlap between NAFLD/NASH and the metabolic syndrome. These findings may lead to new perspectives in early diagnosis, identification of novel biomarkers, and providing novel targets for pharmacological interventions.

Identifiants

pubmed: 34677409
pii: metabo11100694
doi: 10.3390/metabo11100694
pmc: PMC8541039
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Metabolomics. 2014;10(3):461-472
pubmed: 24772056
Metab Syndr Relat Disord. 2019 Dec;17(10):505-511
pubmed: 31589552
Mol Cells. 2015 Jul;38(7):587-96
pubmed: 26072981
Metabolomics. 2021 Jan 16;17(2):12
pubmed: 33458794
Prostaglandins Leukot Essent Fatty Acids. 2004 Mar;70(3):243-51
pubmed: 14769483
Ann N Y Acad Sci. 2010 Jun;1199:1-14
pubmed: 20633104
Proteins. 1997 Jan;27(1):9-25
pubmed: 9037708
J Hepatol. 2018 Feb;68(2):280-295
pubmed: 29154964
J Biol Chem. 1962 Jun;237:1787-92
pubmed: 14470343
Circulation. 2005 Oct 25;112(17):2735-52
pubmed: 16157765
Clin Gastroenterol Hepatol. 2016 Oct;14(10):1463-1472.e6
pubmed: 27317851
Ann Intern Med. 2005 Nov 15;143(10):722-8
pubmed: 16287793
Lipids. 2010 Oct;45(10):893-905
pubmed: 20354806
Diabetes. 2005 Nov;54(11):3140-7
pubmed: 16249437
J Nutr. 2018 Jul 1;148(7):1150-1159
pubmed: 29893901
Nutr Metab Cardiovasc Dis. 2016 Jul;26(7):637-642
pubmed: 27134061
Endocr Rev. 2008 Dec;29(7):777-822
pubmed: 18971485
Nutrients. 2019 Jan 26;11(2):
pubmed: 30691143
Hepatology. 2013 Apr;57(4):1394-406
pubmed: 23299969
EBioMedicine. 2016 Nov;13:157-167
pubmed: 27843095
Clin Mol Hepatol. 2017 Mar;23(1):1-12
pubmed: 28268262
Nutr Diabetes. 2014 Oct 20;4:e141
pubmed: 25329603
Am J Clin Nutr. 2016 Feb;103(2):422-34
pubmed: 26791191
Diabetes Metab. 2019 Apr;45(2):132-139
pubmed: 30266576
EBioMedicine. 2015 Sep 06;2(10):1513-22
pubmed: 26629547
World J Diabetes. 2019 Jan 15;10(1):23-36
pubmed: 30697368
Nat Med. 2015 Mar;21(3):263-9
pubmed: 25686106
Circulation. 2012 May 8;125(18):2222-31
pubmed: 22496159
Sci Rep. 2018 Sep 21;8(1):14200
pubmed: 30242179
Mol Metab. 2016 Oct 31;6(1):38-47
pubmed: 28123936
J Am Geriatr Soc. 2012 Apr;60(4):707-12
pubmed: 22417789
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
Nature. 2008 Jun 5;453(7196):783-7
pubmed: 18454136
J Pharmacol Exp Ther. 2019 Jul;370(1):92-103
pubmed: 31043436
Diabet Med. 1998 Jul;15(7):539-53
pubmed: 9686693
Mol Nutr Food Res. 2017 Dec;61(12):
pubmed: 28949074
Diabetes Care. 2016 Apr;39(4):582-8
pubmed: 26895884
Liver Int. 2015 Jul;35(7):1853-61
pubmed: 25533197
Am J Clin Nutr. 2011 Jan;93(1):186-91
pubmed: 21084651
PLoS One. 2014 Apr 02;9(4):e93148
pubmed: 24695116
Nutr Res. 2012 Sep;32(9):669-675.e3
pubmed: 23084639
Metabolites. 2020 May 15;10(5):
pubmed: 32429287

Auteurs

Cristina Piras (C)

Department of Biomedical Sciences, University of Cagliari, 09042 Monserrato, Italy.

Antonio Noto (A)

Department of Biomedical Sciences, University of Cagliari, 09042 Monserrato, Italy.

Luciano Ibba (L)

Department of Biomedical Sciences, University of Cagliari, 09042 Monserrato, Italy.

Martino Deidda (M)

Department of Medical Sciences and Public Health, University of Cagliari, 09042 Monserrato, Italy.

Vassilios Fanos (V)

Neonatal Intensive Care Unit, Department of Surgical Sciences, University of Cagliari, 09042 Monserrato, Italy.

Sandro Muntoni (S)

Department of Biomedical Sciences, University of Cagliari, 09042 Monserrato, Italy.

Vera Piera Leoni (VP)

Department of Biomedical Sciences, University of Cagliari, 09042 Monserrato, Italy.

Luigi Atzori (L)

Department of Biomedical Sciences, University of Cagliari, 09042 Monserrato, Italy.

Classifications MeSH